Compare Merck & Co., Inc. (MRK) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Teradyne, Inc. — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Teradyne, Inc. trades at $372.62 (market cap $52.25B). The key difference: Merck & Co., Inc. is far larger — about 5.9× Teradyne, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | TER | |
|---|---|---|
Market Cap | $307.25B | $52.25B |
Sector | Health | Technology |
52-Week High | $129.52 | $483.84 |
52-Week Low | $77.60 | $90.15 |
Enterprise Value | $350.66B | $52.08B |
Dividend Yield | 2.73% | 0.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Teradyne (TER) trades at $374.15, up 16.07% in 24 hours, with strong quarterly earnings beats and robust AI-driven semiconductor testing demand. The stock shows bearish technical signals but maintains solid fundamentals with 22.55% net income margin and 28.75% ROE. Recent institutional activity includes Amova Asset Management reducing its position by 49.5% in Q1 2026 while maintaining bullish analyst consensus.
TER presents compelling growth potential from AI infrastructure expansion but faces valuation concerns with a 61.92 P/E ratio. The upcoming Q2 2026 earnings report on July 28, 2026, will be crucial for validating the AI-driven growth narrative. Risks include competitive pressures and market volatility, though analyst consensus targets $459.60 suggest 23% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
